Allos' PDX Yields Positive Interim Data in PTCL Trial
                   
tmcnet.com     May 15, 2008            

Top-Line Results By Year-End As the industry prepared for the first deluge of American Society of Clinical Oncology (ASCO) data Thursday night, cancer drug company Allos Therapeutics Inc. managed to capture a little attention of its own early in the day by reporting promising interim data from... [read full story]                

Add a comment to the article
Type the code shown

View all news articles about:

- Related Topics

View other selected articles:

                   

Tobacco Plants & Cancer Vaccine, Topamax & Birth Defects, Deep Brain Stimulation for Depression

insidermedicine.com     1 hr ago   21 related          

From Chicago - According to research in the Proceedings of the National Academy of Science, tobacco plants, typically known as a cause of cancer, may also help to fight the disease. Researchers infected tobacco plants with a...                

comments

                   

Tribute: Frankie Kannard was master showman, master musician

kansascity.com     1 hr ago          

Who: Frankie Kannard, known as Buster Jenkins, of Ottawa. When and how he died: June 29 of cancer. First a sailor: Buster Jenkins was the stage name of Frankie Kannard. Born in 1926 in tiny Rose, Kan., he joined the Merchant...                

comments

Progen terminates Phase III liver cancer trial

pharmaceutical-business-review.com     2 hrs ago   5 related          

Australia-based biotechnology company Progen Pharmaceuticals has discontinued the PI-88 Phase III study in liver cancer. The company said that the trial is unlikely to meet the forecast patient recruitment timetable and further...                

comments

MethylGene and Celgene suspend enrollments into tumor drug study

pharmaceutical-business-review.com     2 hrs ago   6 related          

MethylGene and Celgene have announced that, at the recommendation of a standing internal safety committee, the companies are temporarily suspending enrollment of new patients into clinical trials evaluating MGCD0103. This...                

comments